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Abstract
Background: A spontaneous de novo mutation is a new mutation appeared in a child that neither the parent
carries. Recent studies suggest that recurrent de novo loss-of-function mutations identified in patients with sporadic
autism spectrum disorder (ASD) play a key role in the etiology of the disorder. POGZ is one of the most recurrently
mutated genes in ASD patients. Our laboratory and other groups have recently found that POGZ has at least 18
independent de novo possible loss-of-function mutations. Despite the apparent importance, these mutations have
never previously been assessed via functional analysis.
Methods: Using wild-type, the Q1042R-mutated, and R1008X-mutated POGZ, we performed DNA-binding
experiments for proteins that used the CENP-B box sequence in vitro. Data were statistically analyzed by one-way
ANOVA followed by Tukey-Kramer post hoc tests.
Results: This study reveals that ASD-associated de novo mutations (Q1042R and R1008X) in the POGZ disrupt its
DNA-binding activity.
Conclusions: Here, we report the first functional characterization of de novo POGZ mutations identified in sporadic
ASD cases. These findings provide important insights into the cellular basis of ASD.
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Background
The genetic etiology of autism spectrum disorder (ASD)
remains poorly understood. A spontaneous de novo mu-
tation is a new mutation appeared in a child that neither
the parent carries. Recent next-generation sequencing
studies have demonstrated that de novo mutations
greatly contribute to the risk of ASD and often produce
large effects [1–5]. In particular, genes with highly recur-
rent de novo possible loss-of-function mutations play
key roles in the etiology of this disorder. De novo muta-
tions in multiple (≥3) unrelated patients have been iden-
tified in several such high-confidence ASD risk genes,
including CHD8, ARID1B, SYNGAP1, DYRK1A, SCN2A,
ANK2, ADNP, DSCAM, CHD2, KDM5B, SUV420H1,
GRIN2B, ASH1L, and POGZ [5]. Among these 14 genes,
POGZ is one of the most recurrently mutated genes in
ASD patients [4, 5]. Our laboratory and other groups
have recently found that POGZ has at least 18 inde-
pendent de novo possible loss-of-function mutations
(Fig. 1, upper) [4–8]. Therefore, de novo mutations in
POGZ can be strongly associated with ASD risk; how-
ever this association requires experimental validation.
Despite the apparent importance, these mutations have
never previously been assessed via functional analysis.
Here, we report that ASD-associated de novo muta-
tions in the POGZ disrupt the DNA-binding activity of
POGZ. These findings provide insight into the cellular
basis of ASD. In addition, de novo POGZ mutations
are frequently found also in patients with intellectual
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disability (ID) [7, 9–11] (Fig. 1, lower). Our current
findings may also help to understand the molecular eti-
ology of ID.
Methods
Cell culture and DNA transfection
Human POGZ cDNA was purchased from DNAFORM
(clone ID: 30745658, Kanagawa, Japan), amplified via
PCR, and subcloned into a pcDNA-6Myc expression
vector. Single amino acid mutants of POGZ were gener-
ated using a KOD mutagenesis kit (Toyobo, Osaka,
Japan) in accordance with the manufacturer’s instruc-
tions. HEK293T cells were cultured in Dulbecco’s Modi-
fied Eagle Medium supplemented with 10 % fetal bovine
serum and were transfected using TransIT Transfection
Reagent (Takara, Ohtsu, Japan). Two days later, cells
were harvested and lysed with TNE buffer (50 mM
Tris–HCl (pH 7.5); 100 mM NaCl; 5 mM EDTA; 0.1 %
(w/v) NP-40) for the DNA-binding assay [12].
Antibodies
Antibodies used in this study were obtained commercially
and included antibodies against POGZ (Sigma-Aldrich,
MO, USA), Tuj1 (Covance, CA, USA), GAPDH (Millipore,
MA, USA), Histone H3 (Cell Signaling, MA, USA), and
Myc (9E10) (Santa Cruz, CA, USA).
Cortical neuronal cultures and neuron
immunocytochemistry
Cortical cultures were prepared from E16.5 embryonic
mouse cortex in minimum essential medium with B27
supplement and 5 % fetal bovine serum and plated on
glass coverslips coated with poly-L-lysine, as previously
described [13]. Neuron immunocytochemistry (at 7 days
in vitro) was performed as previously described [13].
Preparation of cytosolic and nuclear fractions
The preparation of cytosolic and nuclear fractions from dis-
sociated cortical neurons (at 7 days in vitro) was performed
using a Cytoplasmic & Nuclear Protein Extraction Kit
(101Bio, CA, USA) in accordance with the manufacturer’s
instructions.
Immunoblotting
Bead-bound proteins and lysates were resolved by SDS-
PAGE and transferred to polyvinylidene difluoride mem-
branes. Subsequently, these membranes were probed
with the indicated antibodies. Data acquisition and ana-
lysis were performed using an LAS 4000 image analyzer
(GE Healthcare, NJ, USA).
Assay for POGZ-CENPB-DB domain binding
HEK293T cell lysates expressing virtually equivalent levels
of Myc-tagged wild-type or mutant POGZ were prepared.
These lysates were mixed with 10 μg of a 3’-biotinylated
DNA fragment carrying the CENP-B box sequence [14]
and with NeutrAvidin beads (30 μl, 50 % slurry, Thermo
Scientific, MA, USA) for 4 h at 4 °C. After incubation, the
beads were collected and washed 4 times with TNE buffer.
For quantification, the precipitated POGZs were normal-
ized to each POGZ level in total lysates. The background
level was set to the band intensity for the precipitated
R1008X POGZ mutant. The levels of precipitated POGZs
were normalized to each POGZ level in total lysates. Data
Fig. 1 Schematic structure of POGZ and its putative functional domains. The ASD-(upper) and ID- (lower) associated de novo mutations are
indicated below the protein. Bold mutations, common de novo mutations between ASD and ID. Note that the R1001X mutation was found in ID
and ASD/ID patients. X, nonsense; del, deletion; fs, frameshift; *, premature stop codon
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were statistically analyzed by one-way ANOVA followed
by Tukey-Kramer post hoc tests. Differences were consid-
ered significant if p < 0.05.
Results
POGZ encodes a heterochromatin protein 1α-binding
protein that contains a zinc-finger cluster, an HP1-
binding motif, a centromere protein-B-like DNA-
binding (CENPB-DB) domain, and a transposase-derived
DDE domain [15]. Thus, it has been suggested that
POGZ functions as a chromatin regulator [15]. In ac-
cordance with this hypothesis, we found that POGZ was
localized to the nucleus in neurons (Fig. 2a); however,
the function of POGZ in the central nervous system is
unknown. We recently discovered a Q1042R amino acid
substitution within the CENPB-DB domain in sporadic
ASD cases (Fig. 1, upper) [8]. Given that the CENPB-DB
domain is likely to be involved in CENP-B box
sequence-specific DNA-binding [14], this substitution
may affect the DNA-binding activity of POGZ. To exam-
ine this possibility, we performed DNA-binding experi-
ments for proteins that used the CENP-B box sequence
(Fig. 2b) [14]. We prepared HEK293T cell lysates ex-
pressing virtually equivalent levels of Myc-tagged wild-
type, Q1042R-mutated, and R1008X-mutated POGZ
(Fig. 2b, left, lower). These lysates were mixed with the
DNA fragment carrying the CENP-B box sequence. The
levels of precipitated POGZs were normalized to each
POGZ level in total lysates (Fig. 2b, right). We found
that wild-type POGZ co-precipitated well with the DNA
fragment carrying the CENP-B box sequence, a clear in-
dication of binding between wild-type POGZ and the
CENP-B box sequence (Fig. 2b). Interestingly, the
Q1042R mutation was associated with a reduction of ap-
proximately 60 % in DNA-binding, suggesting that
Q1042 is important for the DNA-binding activity of
POGZ (Fig. 2b). We also examined the DNA-binding ac-
tivity of POGZ carrying the ASD-associated R1008X de
novo mutation; this mutation results in a truncated pro-
tein that lacks the entire CENPB-DB domain. We found
that POGZ with this mutation did not co-precipitate
with the DNA fragment (Fig. 2b), indicating the import-
ance of the CENPB-DB domain to the DNA-binding ac-
tivity of POGZ.
Discussion
Recently, POGZ is found to be important for normal
learning in a habituation paradigm in Drosophila [7];
however, the significance of disease-associated de novo
mutations remains unclear. Here, we report the first
functional characterization of de novo POGZ mutations
identified in sporadic ASD cases. Our results indicate
that ASD-associated de novo mutations disrupt the
DNA-binding activity of POGZ, an effect likely to result
a
b
Fig. 2 ASD-associated de novo R1008X and Q1042R mutations disrupt the DNA-binding activity of POGZ. a POGZ is localized to the nucleus in
dissociated embryonic cortical neurons (7 days in vitro). left, Double immunostaining for POGZ (green) and a neuron marker, Tuj1 (red). Nuclei
were stained with Hoechst 33258 (blue). Scale bar, 10 μm. right, Biochemical preparation of the cytosolic and nuclear fractions from dissociated
neurons. Equal quantities of protein were loaded into individual lanes and probed with antibodies against POGZ, GAPDH (a cytosolic marker), and
Histone H3 (a nuclear marker). b Wild-type (WT) but not R1008X POGZ binds a CENP-B box sequence. left, Representative western blots. right,
Quantification of DNA-binding activity. Notably, the Q1042R mutation led to a reduction of approximately 60 % in DNA binding (each n = 6,
*p < 0.05, **p < 0.01, one-way ANOVA followed by Tukey-Kramer post hoc tests (vs. WT)). The averaged WT value was set to 100 %. Data are
expressed as the means ± SEM
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in the perturbation of chromatin function and the neur-
onal transcription network. Given that chromatin regula-
tion plays an essential role in gene expression and
cellular function, the disruption of chromatin-related
mechanisms causes pathological effects on brain func-
tion [2, 16]. Importantly, 8 out of 14 recurrently mutated
high-confidence ASD risk gene products, including
POGZ, ADNP, ARID1B, CHD2, KDM5B, SUV420H1,
ASH1L, and CHD8, are likely to be chromatin regulators
[5]; this finding indicates the critical involvement of
chromatin regulation and function in the etiology of
ASD [2, 16]. Interestingly, it has been suggested that
POGZ cooperatively regulates chromatin structure and
gene expression during human neurodevelopment in
combination with a chromatin modifier CHD8, which
harbors the largest number of loss-of-function mutations
in sporadic ASD [5, 17–19]. Taken together, these find-
ings indicate that both POGZ and CHD8 may be
strongly associated with ASD risk; however the way in
which these disruptive de novo mutations of chromatin
regulators are involved in ASD risk remains unclear
[17–19]. It is important to identify the transcriptional
targets of POGZ and CHD8 as well as the biological sig-
nificance of the disruptive de novo mutations.
Many genes are shown to be associated with ID as well
as ASD. Recent studies show that candidate ID- and ASD-
associated genes are likely to be largely overlapping [20].
As expected, in addition to ASD [4–8], de novo POGZ
mutations are frequently found also in patients with intel-
lectual disability [7, 9–11]. Patients with POGZ mutations
show borderline-moderate ID [7] and lower IQ score [8].
Therefore, identification of the significance of disease-
associated de novo mutations in the POGZ may unravel
the common neural systems associated with ASD and ID.
Conclusions
Our current results, which indicate that de novo muta-
tions in POGZ impair the DNA-binding activity of
POGZ, significantly contribute to understanding the mo-
lecular link between chromatin remodeling and ASD.
Further analysis of the function of de novo mutations in
chromatin regulators will provide important clues to the
molecular pathophysiology of ASD.
Abbreviations
ASD: autism spectrum disorder; CENPB-DB: centromere protein-B-like DNA
binding.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KM, TN, RH, and HH designed the study. KM, TN, KN, NGN, AK, AHT, and NS,
performed biochemical analysis. All authors interpreted the results. TN and
HH wrote the manuscript. All authors participated in the critical revision of
the manuscript for assessing important intellectual content. All authors read
and approved the manuscript.
Acknowledgements
This work was supported by Grants-in-Aid for Scientific Research (B) (15H04645)
(T.N.), (B) (26293020) (H.H.), (C) (15 K09865) (Y.Y.), a Grant-in-Aid for Challenging
Exploratory Research (26670122) (H.H.), (15 K14963) (T.N.), and a Grant-in-Aid for
the Program for Advancing Strategic International Networks to Accelerate the
Circulation of Talented Researchers (S2603) (H.H.) from the Japan Society for the
Promotion of Science; Grants-in-Aid for Scientific Research on Innovative Areas
(15H01288 (H.H.) and 15H01286 (T.N.)) from The Ministry of Education, Culture,
Sports, Science, and Technology, Japan; and research grants from the Uehara
Memorial Foundation, Japan (R.H.), the Program for Creating Future Wisdom,
Osaka University (selected in 2014; T.N. and R.H.), and the Takeda Science
Foundation (T.N.).
Author details
1Laboratory of Molecular Neuropharmacology, Graduate School of
Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka
565-0871, Japan. 2iPS Cell-Based Research Project on Brain
Neuropharmacology and Toxicology, Graduate School of Pharmaceutical
Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
3Department of Psychiatry, Osaka University Graduate School of Medicine,
D3, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan. 4Molecular Research
Center for Children’s Mental Development, United Graduate School of Child
Development, Osaka University, Kanazawa University, Hamamatsu University
School of Medicine, Chiba University and University of Fukui, 2-2,
Yamadaoka, Suita, Osaka 565-0871, Japan.
Received: 11 March 2016 Accepted: 13 April 2016
References
1. O’Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Giriajan S, et al. Exome
sequencing in sporadic autism spectrum disorders identifies severe de novo
mutations. Nat Genet. 2011;43:585–9.
2. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al.
Synaptic, transcriptional and chromatin genes disrupted in autism. Nature.
2014;515:209–15.
3. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The
contribution of de novo coding mutations to autism spectrum disorder.
Nature. 2014;515:216–21.
4. Krumm N, O’Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism
genetics and molecular neuroscience. Trends Neurosci. 2014;37:95–105.
5. Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE, et al.
Insights into autism spectrum disorder genomic architecture and biology
from 71 risk loci. Neuron. 2015;87:1215–33.
6. Fukai R, Hiraki Y, Yofune H, Tsurusaki Y, Nakashima M, Saitsu H, et al. A case
of autism spectrum disorder arising from a de novo missense mutation in
POGZ. J Hum Genet. 2015;60:277–9.
7. Stessman HAF, Willemsen MH, Fenckova M, Penn O, Hoischen A, Xiong B,
et al. Disruption of POGZ is associated with intellectual disability and autism
spectrum disorders. Am J Hum Genet. 2016;98:541–52.
8. Hashimoto R, Nakazawa T, Tsurusaki Y, Yasuda Y, Nagayasu K, Matsumura K,
et al. Whole-exome sequencing and neurite outgrowth analysis in autism
spectrum disorder. J Hum Genet. 2016;61:199–206.
9. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM,
Willemsen MH, et al. Genome sequencing identifies major cause of severe
intellectual disability. Nature. 2014;511:344–7.
10. Tan B, Zou Y, Zhang Y, Zhang R, Ou J, Shen Y, et al. A novel de novo POGZ
mutation in a patient with intellectual disability. J Hum Genet. 2016. doi:10.
1038/jhg.2015.156.
11. White J, Beck CR, Harel T, Posey JE, Jhangiani SN, Tang S, et al. POGZ truncating
alleles cause syndromic intellectual disability. Genome Med. 2016;8:3.
12. Nakazawa T, Komai S, Watabe AM, Kiyama Y, Fukaya M, Arima-Yoshida F,
et al. NR2B tyrosine phosphorylation modulates fear learning as well as
amygdaloid synaptic plasticity. EMBO J. 2006;25:2867–77.
13. Nakazawa T, Kuriu T, Tezuka T, Umemori H, Okabe S, Yamamoto T.
Regulation of dendritic spine morphology by an NMDA receptor-associated
Rho GTPase-activating protein, p250GAP. J Neurochem. 2008;105:1384–93.
14. Masumoto H, Masukata H, Muro Y, Nozaki N, Okazaki T. A human
centromere antigen (CENP-B) interacts with a short specific sequence in
alphoid DNA, a human centromeric satellite. J Cell Biol. 1989;109:1963–73.
Matsumura et al. Journal of Molecular Psychiatry  (2016) 4:1 Page 4 of 5
15. Nozawa R, Nagao K, Masuda HT, Iwasaki O, Hirota T, Nozaki, et al. Human
POGZ modulates dissociation of HP1alpha from mitotic chromosome arms
through Aurora B activation. Nat Cell Biol. 2010;12:719–27.
16. Suliman R, Ben-David E, Shifman S. Chromatin regulators, phenotypic
robustness, and autism risk. Front Genet. 2014;5:81.
17. Cotney J, Muhle RA, Sanders SJ, Liu L, Willsey AJ, Niu W, et al. The autism-
associated chromatin modifier CHD8 regulates other autism risk genes
during human neurodevelopment. Nat Commun. 2015;6:6404.
18. Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, et al.
Coexpression networks implicate human midfetal deep cortical projection
neurons in the pathogenesis of autism. Cell. 2013;155:997–1007.
19. Bourgeron T. From the genetic architecture to synaptic plasticity in autism
spectrum disorder. Nat Rev Neurosci. 2015;16:551–63.
20. Srivastava AK, Schwartz CE. Intellectual disability and autism spectrum
disorders: causal genes and molecular mechanisms. Neurosci Biobehav Rev.
2014;46:161–74.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Matsumura et al. Journal of Molecular Psychiatry  (2016) 4:1 Page 5 of 5
